Anup Radhakrishnan - Sep 18, 2024 Form 4 Insider Report for CARGO Therapeutics, Inc. (CRGX)

Role
Chief Financial Officer
Signature
/s/ Halley Gilbert, as attorney-in-fact for Anup Radhakrishnan
Stock symbol
CRGX
Transactions as of
Sep 18, 2024
Transactions value $
-$32,404
Form type
4
Date filed
9/20/2024, 05:23 PM
Previous filing
Mar 4, 2024
Next filing
Nov 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRGX Common Stock Options Exercise $8.05K +1.6K +24.82% $5.03 8.05K Sep 18, 2024 Direct
transaction CRGX Common Stock Sale -$40.5K -1.6K -19.89% $25.28 6.45K Sep 18, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRGX Stock Option (Right to Buy) Options Exercise $0 -1.6K -2.92% $0.00 53.2K Sep 18, 2024 Common Stock 1.6K $5.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 28, 2024.
F2 This transaction was executed in multiple trades in prices ranging from $25.25 to $25.44, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 25% of the shares subject to the option vest on the first anniversary measured from February 9, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.